Consensus statement on proton therapy for prostate cancer

the Genitourinary Subcommittee of the Particle Therapy Co-Operative Group

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Proton therapy is a promising but controversial treatment in the management of prostate cancer. Despite its dosimetric advantages when compared with photon radiation therapy, its increased cost to patients and insurers has raised questions regarding its value. Multiple prospective and retrospective studies have been published documenting the efficacy and safety of proton therapy for patients with localized prostate cancer and for patients requiring adjuvant or salvage pelvic radiation after surgery. The Particle Therapy Co-Operative Group (PTCOG) Genitourinary Subcommittee intends to address current proton therapy indications, advantages, disadvantages, and cost effectiveness. We will also discuss the current landscape of clinical trials. This consensus report can be used to guide clinical practice and research directions.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalInternational Journal of Particle Therapy
Issue number2
StatePublished - Sep 1 2021

All Science Journal Classification (ASJC) codes

  • Atomic and Molecular Physics, and Optics
  • Radiology Nuclear Medicine and imaging


  • Particle therapy
  • Prostate cancer
  • Proton therapy
  • Radiation therapy


Dive into the research topics of 'Consensus statement on proton therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this